Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 9/20 | 0.61 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.43 |
| ▸ | HTR3B | O95264 | 4/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21237245 | 0.89 | HTR3A (0.46) | HTR3ASOS1KDM4E | |
| SCHEMBL21237242 | 0.88 | HTR3A (0.44) | HTR3AHRH4SOS1KDM4E | |
| SCHEMBL21237246 | 0.85 | CREBBP (0.44) | HTR3ACYP1A2CYP2C19SOS1KDM4E | |
| SCHEMBL21237355 | 0.85 | HTR3A (0.40) | HTR3ATNKSSOS1 | |
| SCHEMBL21237514 | 0.84 | HTR3A (0.44) | HTR3ATNKSHRH4CYP1A2CYP2C19 | |
| SCHEMBL19662780 | 0.82 | HTR3A (0.66) | HTR3ATNKSHRH4CYP1A2HTR3E | |
| SCHEMBL23761963 | 0.81 | HTR3A (0.64) | HTR3ATNKSHRH4CYP1A2HTR3E | |
| SCHEMBL21237335 | 0.80 | CREBBP (0.40) | HTR3ASOS1 | |
| SCHEMBL21237243 | 0.80 | CREBBP (0.43) | HTR3AKMT2A | |
| SCHEMBL21237341 | 0.80 | CREBBP (0.43) | HTR3ASOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247989-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, CREBBP | HTR3A 3917/4885TNKS 1579/4885HRH4 1313/4885 |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | HTR3A 3917/4885TNKS 1579/4885HRH4 1313/4885 |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | HTR3A 3917/4885TNKS 1579/4885HRH4 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.